Scientists and staff from academic research institutes and the pharma industry will be able to be informed on the latest trends and challenges within the field of oncology at the Sartorius Research Xchange Forum 2017.
Sartorius
The forum is taking place on 22-23 February in Goettingen Germany and will be hosted by the international pharma and laboratory supplier Sartorius.
A range of keynote presentations will be given by recognised industry scientists and representatives from research and development who will provide information on the latest developments specific to cancer research and therapies.
Insights into gene therapies and cancer immunotherapy using monoclonal antibodies will take place as well as a focus on DNA repair mechanisms, drug delivery and cancer stem cell research.
Professor Maja Banks-Köhn of the European Molecular Biology Laboratory (EMBL) will report on new interdisciplinary approaches in the inhibition of cancer-promoting phosphatases.
Highlights at the forum include: the role and potential of on-coding RNAs, cellular microenvironment and cancer, state of the art antibody drug conjugates and more.
Michael Melingo, member of the Group Executive Committee and president of the Lab Products and Services Division at Sartorius said: “As a leading pharmaceutical and laboratory equipment supplier, we are well aware of the challenges of translating research findings into clinical practice. With this Forum, we aim to offer our customers and all those engaged in this field a platform for entering into a dialog and to accelerate this translation process.”
Recent market figures show that cancer therapy drugs account for almost 90% of late phase clinical trials in the drug discovery industry. Oncology is dependent upon collaboration between drug discovery ad applied research to progress.
“We are consistently implementing a number of measures to enable researchers to reach these goals faster by breakthrough innovations, such as the new cell analysis platform for immuno-oncology, which has been integrated into the Sartorius portfolio following the acquisition of IntelliCyt,” stated Terry Dunlay, who heads the Bioanalytics unit.
“Cancer challenges us from both a social and a business perspective. In sharing information with our customers, we experience on a daily basis how important it is to transfer knowledge from drug discovery into effective treatment. With our Xchange Forum, we would primarily like to offer new ideas and inspiration to participants for their work,” said Karen Storm, vice president of Marketing of the Lab Products & Services Division.